High up on the top shelf of the old corner-store candy shop where you’d idle over your favorites―Wonka Sweetarts, Atomic Fireballs, Curley Wurleys, Big League Chew―not caring, nor should you have, that you’d smashed your piggy bank just for a taste of the sweet sugar that would launch you into a euphoric sugar high. The 60s and 70s were more forgiving on the impact sugar has on our health; but today millions of people feel the effects that sugar had on an entire generation.

The sugar industry and brands profited while obesity and diabetes grew (29 million Americans suffer from diabetes today, and an astounding 32 percent of Americans are obese). Today’s cannabis industry, one of the newest and fastest growing, relies heavily on the use of sugar in, coincidently, their fastest growing product: edibles.


Still in its infancy and growing fast, cannabis edible producers are at a fork in the road. Very soon, if not already, they’ll be forced to follow a similar pattern that the likes of Coca-Cola, Pepsi and Wrigley adhered to decades ago by eliminating sugar, or offering sugar-free alternatives.

“The cannabis industry has a taste problem,” says Chris Bunka, CEO of Lexaria Bioscience (CSE:LXX, OTCQB:LXRP) , a health company developing technology that will help producers mask the taste of cannabis without the use of sugar. “Companies load up edibles with sugar to mask the flavor. Medical patients do not want 800 calories a day of sweetened cannabis products. They need more healthy ways of transmitting cannabis into the bloodstream.”

Today, sugar-free products are commonplace. Even beer drinkers have a sugar-free option, Stepa, a Belgian beer that with its 11 percent taste rating certainly leaves room for improvement. Light beer has significantly less sugar than regular beer, and in the US, it dominates sales with Bud Light, Coors Light and Miller Lite leading all domestic beer brand sales in 2017. While food and drink brands have figured out how to maintain quality of taste by using artificial sweeteners, cannabis producers face a challenge that concerns the loss of benefits that cannabis products contain.

“Currently, stripping out the taste of cannabis weakens the benefits of the product,” explains John Docherty, President of Lexaria. “Many manufacturers remove elements of the cannabis oil extracts in an effort to eliminate the strong flavor before integrating the adulterated, or diluted, oil into the edible.”

Docherty continues: “While this can certainly lend to flavor improvements, leading edge medical research and cannabis experts would argue that the full medical benefits of the plant can only be attained in its whole form.”

But there is a fix.

How to Make Sugar-Free Cannabis Edibles

“Technologies that employ long-chain fatty acid molecular transformation of the active substance in cannabis are designed to integrate whole plant extracts into edibles without unwanted flavors, or unwanted sweeteners,” explains Doherty.

Lexaria’s technology masks the strong taste inherent in cannabis edibles by placing the active cannabinoids inside fatty acids which prevents them from being drawn to the tongue’s bitter taste receptors. The technology eliminates the need for sugar additives, resulting in a better tasting and healthier cannabis edible that’s integral in attracting new medical cannabis users.

“Although experienced cannabis users enjoy the flavor profile of edibles, most new users and the overwhelmingly largest potential slice of new market belongs to people who will use cannabis products more gingerly,” says Bunka. “The huge market potential of new and future users will be exploited by low-calorie products that taste similar to the food they are infused with. The largest segment of growth going forward will be in low-calorie, good tasting cannabis edibles.”

This technology has many additional benefits including drastically improved absorption rates and decreasing the time it takes for effects to kick in.

This INNspired Article is brought to you by:

Lexaria Bioscience (CSE:LXX,OTCQB:LXRP) is a technology company with a robust patent portfolio for the improved delivery of bioactive compounds. The company is leveraging its proprietary technology for better-tasting, faster-acting and more potent cannabis edibles.Send me an Investor Kit

A Market High on Edibles

Total current sales of cannabis are at $6.9 billion, a 30 percent increase year-over-year, with an estimated 40-60 percent of that number coming from edibles. Sales in Colorado doubled from $90.41 million to $189.9 million over the most recent two-year period (2014-2016), and they also outgrew plant-based cannabis sales five-fold―53 percent compared to 11 percent year-over-year. Growth of edibles in Washington increased 121 percent in 2016 from the previous year.

In total, legal cannabis sales in the US and Canada are projected to reach $21.6 billion by 2021, growth that is large and fast was last seen during the dot-com era.

Market Potential

The latest data puts the projected growth of the global sugar-free foods market at a CAGR of 10.16 percent from 2017 to 2021, according to research firm “Research and Markets”.

One driver in the market is a shift toward healthy snacks and beverages. Most consumers now check the ingredients label before purchasing any food or beverage product, specifically, consumers who are conscious of their amount of sugar intake. Higher disposable income has further contributed to this shift, as consumers now can afford to spend more on expensive sugar substitutes, and alternative, sugar-free products that are priced higher than their sugary counterparts.

Coupled with the growth in the cannabis edible market, investors would be smart to pay attention to these trends.

This INNspired article is sponsored by Lexaria Bioscience (CSE:LXX,OCTQX:LXRP). The article was written according to INN editorial standards to educate investors.

Donation will benefit veteran-focused organizations and nonprofits, including all TruVet Program partners

Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a United States -based leading medical cannabis company, announced today a donation for all TruVet Program partners year-to-date in honor of Veterans Day. A total of $15,000 representing a portion of the November proceeds from the Company’s limited-edition Freedom Pre-Roll product, will be shared among program partners, which are veteran-focused organizations andor nonprofits.

Keep reading... Show less

Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Aurora Cannibas, Inc. (“Aurora” or the “Company”) (NYSE:ACB) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Aurora securities between February 13, 2020, and September 4, 2020, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.comacb

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

Keep reading... Show less

Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Aurora Cannibas, Inc. (“Aurora” or the “Company”) (NYSE:ACB) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Aurora securities between February 13, 2020, and September 4, 2020, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.comacb

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

Keep reading... Show less

Hill Street Beverage Company Inc. (TSXV: BEER) (“Hill Street” or the “Company”) reported its first quarter results for period ended Sept 30, 2020. A complete set of financial statements and Management’s Discussion & Analysis has been filed at www.sedar.com. All dollar figures are quoted in Canadian dollars.

FY21 First Quarter Financial Highlights

Keep reading... Show less

Signed LOI for CAD$23 million sale to Ionic provides shareholder value

Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company”) is pleased to announce that it has received and signed a non-binding letter of intent dated November 30, 2020 with IONIC Brands Corp. (“Ionic”) for the proposed sale to Ionic of certain assets held by Lobe related to Cowlitz County Cannabis Cultivation Inc. (“Cowlitz”) (the “Transaction”). Cowlitz is one of the top five licensed cannabis producersprocessors located in Washington State.

The assets being sold to Ionic may include, but are not limited to, the assignment of all property leases relating exclusively to Cowlitz’s business, the assignment of Lobe’s option agreement to acquire all of the outstanding shares of Cowlitz, and the assignment of other contracts and rights related exclusively to Cowlitz including service contracts and equipment leases (the “Assets“).

The Transaction is subject to several closing conditions, including but not limited to: (i) satisfactory due diligence by both Ionic and Lobe; (ii) completion of a definitive agreement with binding terms and conditions for the Transaction, including finalization of the specific Assets that will be sold and certain Cowlitz assets that may be retained by Lobe; (iii) all respective directors and officers of Lobe and Ionic entering into support agreements for the Transaction; (iv) approval by the boards of directors of both Lobe and Ionic; (v) the completion of a share consolidation by Ionic on a minimum of one new Ionic common share for every four and a half (4.5) old Ionic common shares (the “Ionic Consolidation“); (vi) the conversion of all Ionic debentures (with principal amount of approximately CAD$14.7 million) into a secured equity or a similar instrument (“Debt Conversion“); (vii) completion of a concurrent financing by Ionic for gross proceeds of at least US$2 million (the “Ionic Concurrent Financing“); (viii) Ionic having all cease trade orders issued against it lifted(2); (ix) Ionic applying to the CSE for requalification and qualifying for listing and resumption of trading(2); and (x) the receipt of all required shareholder and regulatory approvals, including the approval of the CSE. Following the closing of the Transaction, Ionic’s board of directors is expected to be comprised of five (5) members and Lobe will have the right to appoint two (2) directors to the Ionic board.

The sale price for the Assets shall be a minimum of CAD$23 million, payable through the issuance of Ionic post-consolidation common shares (being approximately 49% of Ionic’s estimated $47 million capitalization post-restructuring (after giving effect to the Ionic Consolidation and Debt Conversion)), prior to giving effect to the Ionic Concurrent Financing. Following the closing of the Transaction, it is expected that the Lobe will own approximately 49% of Ionic’s common shares, on a post-consolidation and pre-Ionic Concurrent Financing basis. Ionic is expected to have a minimum total capitalization valuation of CAD$47 million, pre-Ionic Concurrent Financing.

As previously announced, Lobe has been pursuing strategic alternatives for Cowlitz, aimed at maximizing its value to the Company. Cowlitz reported over US$14.6 million in gross sales revenues for the nine month period ended September 30, 2020, according to data provided on reports to the Washington State Department of Revenues(1). Lobe generates revenues through licensing and leasing agreements in place with Cowlitz.

Ionic is listed on the Canadian Securities Exchange(2) (the “CSE“) (CSE: IONC) and is a growing US-based cannabis company that focuses on premium cannabis products with current operations in Washington and Oregon. Ionic has completed a number of strategic synergistic acquisitions since 2019 aimed at growing revenues as a multi-state operator, and increasing their overall product lines and intellectual property portfolio. Ionic’s strategy has been focused on building a regionalized multistate operation of cannabis brands in the Pacific Northwest markets with an eye to expansion into other recreational markets and aggressive national expansion.

John Gorst, CEO of Ionic said, “We are excited about this opportunity to expand our presence in Washington State. Cowlitz has tremendous brand presence and following in Washington State, which we feel is a natural fit, complementing our existing operations. The combination will make us one of the largest premier cannabis companies in the Pacific Northwest markets. The acquisition of the Cowlitz Assets will represent a complimentary synergistic acquisition that achieves our goal of operational expansion and growth of our product portfolio.”

“The proposed transaction with Ionic is accretive to both parties, successfully meets our M&A initiatives and keeps Lobe active in the cannabis and overall transformation psychedelic medicine space,” states Tom Baird, CEO of Lobe. “The Transaction provides Lobe with significant ownership and board presence in Ionic. With its already significant operations in Washington State and Oregon, we feel Ionic’s proposed product expansion initiatives together with the addition of the Cowlitz Assets can lead to aggressive growth.”

About Ionic Brands Corp.

Ionic is dedicated to building a regionally based multi-state consumer-focused cannabis concentrate brand portfolio with strong roots in the premium and luxury segments of vape concentrates and edibles. The cornerstone brand of the portfolio, IONIC, is the #3 vaporizer brand in Washington State and has aggressively expanded throughout the Pacific Northwest of the United States. The brand is currently operating in Washington and Oregon. Ionic’s strategy is to be the leader of the highest-value segments of the cannabis market.

About Lobe Sciences Ltd.

Lobe is a growth-oriented research, technology & services company that provides financial, management, IP and branding support to businesses. The Company operates a portfolio of companies focused on developing transformational medicines and applies refined strategies to help partner companies reach their full potential. Based in Vancouver, BC, Lobe Sciences creates value through acquisitions and development of assets, products and technologies by leveraging its scientific, engineering, branding and operational expertise supported by strong capital markets acumen.

For further information please contact:

Lobe Sciences Ltd.
Thomas Baird, CEO
info@lobesciences.com
Tel: (949) 505-5623

THE CSE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE.

Disclaimer for Forward Looking Statements

This news release contains forward-looking statements relating to the future operations of the Company and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact included in this release, including statements regarding the future plans and objectives of the Company, the Company’s expectations surrounding its development of treatments and/or therapeutics for mTBI and PTSD, the proposed Transaction and terms with Ionic and estimated capitalization of Ionic and share value to Lobe, Ionic having its cease trader orders lifted and resumption for trading on the CSE, future sales and expected revenues of Cowlitz and enhancing its value to the Company, are forward looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations are risks detailed from time to time in the filings made by the Company with securities regulations. Readers are cautioned that assumptions used in the preparation of the forward-looking statements may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company, including changes to the regulatory environment; and that the current Board and management may not be able to attain the Company’s corporate goals and objectives. As a result, the Company cannot guarantee that any forward-looking statement will materialize and the reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made only as of the date of this news release and the Company does not intend to update any of the included forward-looking statements except as expressly required by applicable Canadian securities laws.

Keep reading... Show less